GW Pharma

Cambridge, United Kingdom Founded: 1998 • Age: 28 yrs Acquired By Jazz Pharmaceuticals
Developer of cannabinoid medicines for MS spasticity, cancer pain and childhood epilepsy

About GW Pharma

GW Pharma is a company based in Cambridge (United Kingdom) founded in 1998 was acquired by Jazz Pharmaceuticals in February 2021.. GW Pharma has raised $46.5 million across 3 funding rounds from investors including Jazz Pharmaceuticals and Mentor Capital. GW Pharma offers products and services including Xywav, Epidiolex, Defitelio, and Rylaze. GW Pharma operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, PureTech Health and Biohaven Pharmaceutical, among others.

  • Headquarter Cambridge, United Kingdom
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Gw Pharma Limited
  • Date of Incorporation 29 Jan, 1999
  • Jurisdiction CAMBRIDGE
Operational Areas
Healthcare → Health Technology & Digital Health
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $46.5 M (USD)

    in 3 rounds

  • Latest Funding Round
    $1 M (USD), Post-IPO

    Mar 03, 2017

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Jazz Pharmaceuticals

    (Feb 03, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of GW Pharma

GW Pharma offers a comprehensive portfolio of products and services, including Xywav, Epidiolex, Defitelio, and Rylaze. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Oral solution for treating narcolepsy and idiopathic hypersomnia

Cannabidiol-based treatment for epilepsy seizures

Therapy for preventing complications in leukemia patients

Recombinant treatment for acute lymphoblastic leukemia

People of GW Pharma
Headcount 1000-5000
Employee Profiles 779
Board Members and Advisors 13
Employee Profiles
People
Shelby Reid
Medical Advisor, Oncology
People
Matt Lasmanis
Chief Digital Officer (cdo)
People
Patricia Carr
Senior Vice President, Chief Accounting Officer
People
Luigia de Flaviis
Senior Research Technologist

Unlock access to complete

Board Members and Advisors
people
Jennifer Cook
Director

Unlock access to complete

Funding Insights of GW Pharma

GW Pharma has successfully raised a total of $46.5M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1 million completed in March 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Post-IPO — $1.0M
  • First Round

    (01 Jun 2003)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2017 Amount Post-IPO - GW Pharma Valuation

investors

Jan, 2006 Amount Series C - GW Pharma Valuation

investors

Jun, 2003 Amount Series C - GW Pharma Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in GW Pharma

GW Pharma has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Jazz Pharmaceuticals and Mentor Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Energy investments and funding for pre-IPO companies in oil, gas, coal, and uranium sectors.
Founded Year Domain Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by GW Pharma

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - GW Pharma

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Gw Pharma Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of GW Pharma

GW Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, PureTech Health and Biohaven Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Drugs for CNS disorders are developed and advanced.
domain founded_year HQ Location
Genetically engineered cell therapies are developed for multiple disorders.
domain founded_year HQ Location
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
domain founded_year HQ Location
Therapies for neurological and neuropsychiatric diseases are developed.
domain founded_year HQ Location
Therapies for psychosis and cognitive impairment are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Gw Pharma

Frequently Asked Questions about GW Pharma

When was GW Pharma founded?

GW Pharma was founded in 1998 and raised its 1st funding round 5 years after it was founded.

Where is GW Pharma located?

GW Pharma is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.

Is GW Pharma a funded company?

GW Pharma is a funded company, having raised a total of $46.5M across 3 funding rounds to date. The company's 1st funding round was a Series C of $31.5M, raised on Jun 01, 2003.

What does GW Pharma do?

GW Pharma was founded in 1998 in Cambridge, United Kingdom, within the pharmaceutical sector. Focus is placed on developing cannabinoid-based treatments, including Sativex for managing spasticity in multiple sclerosis patients and pain in cancer cases, as well as Epidiolex for addressing epilepsy in children. Operations center on research and drug approval processes across Europe and beyond, targeting neurological and pain-related conditions.

Who are the top competitors of GW Pharma?

GW Pharma's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.

What products or services does GW Pharma offer?

GW Pharma offers Xywav, Epidiolex, Defitelio, and Rylaze.

Who are GW Pharma's investors?

GW Pharma has 2 investors. Key investors include Jazz Pharmaceuticals, and Mentor Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available